Research roundup

Debbie Rigby presents the latest research news relevant to pharmacy

Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus

Previous trial results have suggested that DPP4 inhibitors might increase heart failure (HF) risk in patients with type 2 diabetes mellitus (T2DM). Secondary Analysis of the TECOS randomised controlled trial of nearly 15,000 patients shows sitagliptin does not affect the risk for hospitalisation for heart failure. These results were seen overall and among high-risk patient subgroups.

JAMA Cardiol, Published online April 13, 2016.


Functional dyspepsia: new insights into pathogenesis and therapy

One in 10 people suffer from functional dyspepsia, a clinical syndrome com­prising chronic bothersome early satiety, or postprandial fullness, or epigastric pain or burning. Postprandial distress syndrome (PDS) with early satiety and/or postprandial fullness and epigastric pain syndrome (EPS) are clinical subsets of functional dyspepsia. Acid suppression therapy is a first line therapy for EPS, and in PDS, a prokinetic is preferred. Second line therapy includes administration of a tricyclic antidepressant in low doses, or mirtazapine, but not a selective serotonin reuptake inhibitor.

The Korean Journal of Internal Medicine. 2016 Apr 6. [Epub ahead of print]


The gut microbiota and metabolic disease

It is well accepted that obesity predisposes towards type 2 diabetes and cardiovascular disease, and the gut microbiota contributes to adiposity. This paper explores the current understanding and future perspectives of the gut microbiome and the role of diet, prebiotics and probiotics to treat metabolic diseases. The authors suggest that individualized treatment strategies are likely to be required.

J Intern Med 2016.


Asthma control in Australia

A cross-sectional web-based survey conducted in 2012 highlights significant preventable asthma morbidity in Australia. Just over half of the 2686 participants rated their asthma as well-controlled, with “not well controlled” for 22.7% and “very poorly controlled” for 23.0%. 60.8% reported using preventer medication (mostly combined inhaled corticosteroid/long-acting β2-agonist) during the previous year.

Med J Aust 2015; 202 (9): 492-496.


Previous Pharmacists key in cardiac rehabilitation
Next Forum: What’s the go with the 1 July NDSS changes?

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.

No Comment

Leave a reply